Ascendis Pharma's Growth Hormone Deficiency Candidate Outperforms in Phase 3 Trial
Portfolio Pulse from Vandana Singh
Ascendis Pharma A/S (NASDAQ:ASND) reported positive Phase 3 trial results for TransCon hGH, showing superiority over placebo and comparable effects to daily hGH in treating adult growth hormone deficiency. The trial met its primary and key secondary efficacy endpoints, and the treatment was well tolerated with no discontinuations. Ascendis plans to submit a supplemental Biologics License Application to the FDA next year. ASND shares rose 1.15% to $122.28.
December 19, 2023 | 7:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ascendis Pharma's TransCon hGH showed positive results in a Phase 3 trial for adult growth hormone deficiency, with plans to submit for FDA approval next year. The stock price increased by 1.15%.
The positive trial results are a significant milestone for Ascendis Pharma, likely to lead to increased investor confidence and potential FDA approval, which could drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100